Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant
intranasal in the acute treatment of migraine.
* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The
World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee
revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN
) Council for use in the U.S. and is pending formal adoption by the INN for international
use.